Menu
Genetic Technologies Limited (GENE), a molecular diagnostics company focused on cancer risk assessment, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for non-hereditary breast cancer, announced today that it has initiated a strategic review.
Update(s):
December 12, 2017: Genetic Technologies Limited (GENE), a molecular diagnostics company focused on cancer risk assessment, and provider of BREVAGenplus, a first-in-class, clinically validated risk assessment test for non-hereditary breast cancer, is pleased to report that it has entered an important stage of the Company’s strategic review which was announced to the market on 25 August 2017.